Product image of Lenalidomide Grindeks (Lenalidomide) supplied by GNH India

Lenalidomide Grindeks

Active Ingredient:
Lenalidomide
Origin:
EU

Lenalidomide Grindeks (Lenalidomide)

Lenalidomide, the active ingredient in Lenalidomide Grindeks, is an Immunomodulatory imide drug (IMiD) presented as an oral formulation for oral use. It is indicated for the treatment of multiple myeloma and myelodysplastic syndromes with del(5q) in appropriate patients.

GNH India supplies Lenalidomide Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Grindeks

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lenalidomide is used in hematologic malignancies and related disorders, acting on abnormal plasma cells and dysplastic marrow clones.

  • Multiple Myeloma: improves disease control and prolongs progression‑free survival.
  • Myelodysplastic Syndromes with del(5q): reduces transfusion requirements and may improve blood counts.
  • Relapsed or refractory disease: offers an option when prior therapies have failed.

How It Works

  • Lenalidomide binds to the cereblon component of the CRL4‑CRBN E3 ubiquitin ligase complex, altering its substrate specificity. This leads to ubiquitination and proteasomal degradation of transcription factors Ikaros and Aiolos, resulting in anti‑angiogenic, immunomodulatory, and direct anti‑tumor effects that inhibit malignant plasma cell proliferation.

Side Effects

Lenalidomide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

  • Fatigue: persistent tiredness reported by many patients.
  • Diarrhea: mild to moderate gastrointestinal upset.
  • Rash: skin irritation or erythema.
  • Constipation: reduced bowel movements.
  • Nausea: occasional feeling of sickness.
  • Musculoskeletal pain: aches in joints or muscles.

Serious or Rare Side Effects

  • Thromboembolic events: deep vein thrombosis or pulmonary embolism.
  • Severe neutropenia: markedly low neutrophil counts increasing infection risk.
  • Secondary malignancies: rare development of new cancers.
  • Hepatotoxicity: elevated liver enzymes or liver injury.
  • Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
  • Cardiac arrhythmias: irregular heart rhythms in susceptible individuals.

Precautions & Warnings

Before initiating Lenalidomide therapy, clinicians should assess patient history and monitor relevant parameters.

  • Pregnancy risk: avoid use in pregnant women; teratogenic potential requires strict contraception.
  • Thrombosis risk: evaluate for clotting disorders and consider prophylactic anticoagulation.
  • Renal function: adjust monitoring for patients with impaired kidney function.
  • Hepatic function: monitor liver enzymes regularly.
  • Infection vigilance: watch for signs of infection due to neutropenia.
  • Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and light.

Avoid Interactions

Lenalidomide may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers: may reduce plasma concentrations of Lenalidomide.
  • Anticoagulants (e.g., warfarin): increased risk of bleeding.

Moderate Interactions (Monitor Closely)

  • Immunosuppressants: heightened infection risk.
  • P-glycoprotein inhibitors: potential increase in drug exposure.
  • NSAIDs: may exacerbate renal toxicity.
  • Vaccines (live): reduced vaccine efficacy.
  • Other myelosuppressive agents: additive bone‑marrow suppression.

Frequently Asked Questions

Lenalidomide Grindeks is indicated for patients with multiple myeloma and for those with myelodysplastic syndromes that carry the del(5q) chromosomal abnormality. In these settings it helps control disease progression and can reduce the need for blood transfusions.

The drug binds to cereblon, a component of the CRL4‑CRBN E3 ubiquitin ligase complex, changing its target profile. This triggers the degradation of transcription factors Ikaros and Aiolos, leading to anti‑angiogenic, immunomodulatory, and direct anti‑tumor actions that suppress malignant plasma cells.

The specific dose and schedule of Lenalidomide Grindeks are determined by the prescribing clinician based on the patient’s diagnosis, disease stage, renal function, and overall health. Only a qualified healthcare professional can set the appropriate regimen.

Lenalidomide is classified as teratogenic and is contraindicated in pregnancy. Women of child‑bearing potential must use effective contraception before, during, and after treatment. Safety during breastfeeding has not been established, so nursing is generally discouraged while on therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs), and necessary import documentation.

Lenalidomide belongs to the immunomodulatory imide drug class, offering a distinct mechanism from proteasome inhibitors or monoclonal antibodies. It provides oral administration, which can be more convenient, and is often used in combination regimens to enhance efficacy while managing side‑effect profiles.

Store Lenalidomide Grindeks at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed to maintain stability.

Lenalidomide Grindeks is taken orally, usually as a tablet or capsule, with or without food as directed by the prescriber. Patients should follow the exact dosing schedule provided and not alter the regimen without medical advice.

The most serious risks include thromboembolic events such as deep‑vein thrombosis, severe neutropenia leading to infection, secondary malignancies, and rare but severe skin reactions like Stevens‑Johnson syndrome. Patients should be monitored closely for these complications.

Lenalidomide is contraindicated in pregnant women and should be avoided in patients with known hypersensitivity to the drug or its excipients. Caution is also advised for individuals with uncontrolled infections, severe renal impairment, or a history of thromboembolic disease without appropriate prophylaxis.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lenalidomide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT